cilostazol has been researched along with papaverine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bristol, JA; Cain, MH; Weishaar, RE | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, L; Gong, J; Jin, Y; Peng, T; Shi, J; Tong, R; Wei, X; Zhou, Y | 1 |
| Harada, K; Kobayashi, S; Nagakura, N; Saeki, T; Saito, I; Yamanaka, T; Yoshitake, S | 1 |
| Sawada, M; Suzumura, A; Takayanagi, T; Tamaru, T; Yoshikawa, M | 1 |
| Clancy, JP; Cobb, BR; Fan, L; Kovacs, TE; Sorscher, EJ | 1 |
3 review(s) available for cilostazol and papaverine
| Article | Year |
|---|---|
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Calmodulin; Cardiotonic Agents; Guinea Pigs; Humans; Hypersensitivity; In Vitro Techniques; Lung Diseases; Myocardium; Platelet Aggregation; Substrate Specificity | 1985 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Inhibitors of phosphodiesterase as cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasms; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship | 2018 |
4 other study(ies) available for cilostazol and papaverine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Topics: Blood Platelets; Cilostazol; Cyclic AMP; Cyclic GMP; Cyclooxygenase Inhibitors; Fatty Acids, Monounsaturated; Humans; In Vitro Techniques; Isoenzymes; Male; Papaverine; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Thromboxane A2 | 1996 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamole; DNA Primers; Gene Expression Regulation, Enzymologic; Interleukin-1; Interleukin-6; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Papaverine; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazines; Pyrrolidinones; Quinolines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Rolipram; Tetrazoles; Theophylline; Tumor Necrosis Factor-alpha; Vinca Alkaloids; Xanthines | 1999 |
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.
Topics: Adenosine Deaminase; Anions; Cell Line; Chlorine; Cilostazol; Colforsin; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Electrophysiology; Epithelium; Glyburide; Humans; Hypoglycemic Agents; Milrinone; Mutation; Papaverine; Phosphodiesterase Inhibitors; Piperazines; Purines; Receptors, Purinergic P1; Rolipram; Sildenafil Citrate; Sulfones; Tetrazoles; Time Factors | 2003 |